Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

The biopharmaceutical company is focused on hair loss treatments. 


Eli Lilly (LLY) to Buy 5% of Veradermics Stock in IPO

Bell Potter analyst Thomas Wakim maintained a Hold rating on CSL today and set a price target of A$195.00. According to TipRanks, Wakim is an analy...

CSL (CMXHF) Gets a Hold from Bell Potter

The company has committed more than $50 billion to expanding manufacturing. 


Eli Lilly (LLY) to Build $3.5 Billion Manufacturing Plant in Pennsylvania

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report), West Pharmaceutical Servi...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), West Pharmaceutical Services (WST) and Humana (HUM)

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Investors will find all of the hottest stock market news for Friday in our daily wrap-up.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

The investment helps diversify the drug pipeline. 


Eli Lilly (LLY) Inks $1.12 Billion Deal with ‘Gene-Editing’ Firm Seamless

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY – Research Report) and Maravai...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Maravai Lifesciences Holdings (MRVI)

Traders seeking out the hottest stock market stories for Wednesday will find them in our daily warp-up.


Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

The pharma giants are fighting for market share. 


Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli Lilly &...

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Eli Lilly & Co (LLY)

The Trump administration has announced the names of 15 drugs targeted for Medicare price negotiations for 2028. The new list of branded medications...

CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks

Traders seeking the latest stock market news for Monday will find it in the TipRanks daily wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

The new campaign comes as competition heats up. 


Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’

UnitedHealth Group ($UNH) is set to report its Q4 earnings on January 27. Analysts expect revenue of about $113.77 billion, up 12.9% year‑over‑year...

Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Eli Lilly & Co today and set a price target of $1,182.00. According to Tip...

Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Danish drugmaker Novo Nordisk’s ($NVO) shares rose about 3% as data showed that over 18,000 prescriptions were issued in the first week of the laun...

Novo Nordisk Stock (NVO) Gains on Obesity Pill Demand as Goldman Flags Earnings Upside

Novo Nordisk’s ($NVO) new weight-loss pill recorded 18,410 prescriptions in the U.S. during its first full week of availability, according to marke...

Novo Nordisk’s Wegovy Pill Records Nearly 20,000 Prescriptions in First Week

The company’s weight-loss pill is expected to be a blockbuster. 


Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly’s new Phase 1 imaging study, officially titled “A Phase...

Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview Eli Lilly and Company has launched a Phase 3b tria...

Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Travelers Companies (TRV – Research Report) and Ally ...

Analysts Offer Insights on Financial Companies: Travelers Companies (TRV) and Ally Financial (ALLY)

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Charles Schwab (SCHW – Research Report) and Ally Fi...

Analysts Have Conflicting Sentiments on These Financial Companies: Charles Schwab (SCHW) and Ally Financial (ALLY)

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY – Research Report) and Fairfax Financial Hold...

Analysts Offer Insights on Financial Companies: Ally Financial (ALLY) and Fairfax Financial Holdings (OtherFRFHF)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly Advances New Oral Drug for Diabetic Nerve Pain Study Ov...

Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study OverviewA new Eli Lilly phase 4 study, SURMOUNT-REAL UK, is...

Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside

Berenberg Bank analyst maintained a Hold rating on Thales yesterday and set a price target of €265.00. The company’s shares closed yesterday at €26...

Berenberg Bank Sticks to Its Hold Rating for Thales (0IW5)

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co, with a price target of $1,300.00. Accordin...

Eli Lilly & Co (LLY) Gets a Buy from Bernstein

ABVX stock has risen an astounding 1,700%.


Abivax CEO Dismisses Rumors of Eli Lilly (LLY) Takeover as ‘Noise’

In a report released on January 18, Milene Kerner from Barclays maintained a Sell rating on Thales, with a price target of €260.00. Kerner covers t...

Barclays Keeps Their Sell Rating on Thales (0IW5)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report), Spyre Therapeutics (SYRE ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Spyre Therapeutics (SYRE) and Astellas Pharma (OtherALPMF)

U.S. stocks finished the week essentially flat as a semiconductor-led bid was offset by softer bank performance and a steady drumbeat of policy hea...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 18

Kepler Capital analyst Aymeric Poulain maintained a Buy rating on Thales on January 16 and set a price target of €310.00. The company’s shares clos...

Kepler Capital  Reaffirms Their Buy Rating on Thales (0IW5)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview Eli Lilly and Company is running a study called “A...

Eli Lilly’s New Dulaglutide Study Targets Real-World Safety Questions for GLP-1 Investors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company, together with its subsidia...

Eli Lilly Quietly Advances New Oral Candidate With Completion of Phase 1 Study in China

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is running a Phase 1 trial ...

Lilly Advances Next-Wave Obesity Pipeline With Japanese Phase 1 Combo Study

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly’s Olomorasib Capsule Study Offers Fresh Signals for Inv...

Eli Lilly’s Olomorasib Capsule Study Signals Steady Pipeline Progress for Investors

Rival Novo Nordisk is already selling its obesity pill in America. 


Eli Lilly Stock (LLY) Falls 5% After FDA Delays Decision on Weight-Loss Pill

Investors will find the biggest earnings reports, analyst updates, and economic data moving the stock market on Wednesday.


Wall Street has labeled the airline industry as a surprising winner from the growing use of weight-loss drugs. More specifically, with the first GL...

Why GLP-1 Weight-Loss Pills Might Be Great News for Airlines

The brokerage highlights an impressive pipeline of new medications. 


BMO Capital Markets Pounds the Table on Eli Lilly Stock (LLY)

Danish pharmaceutical giant Novo Nordisk ($NVO) is open to big or small deals to bolster its obesity drug portfolio. In an interview with Bloomberg...

Novo Nordisk (NVO) Is Open to M&A to Bolster Obesity Drug Portfolio

The U.S. pharma giant has operated in France for 60 years.  


French Government Shoots Down Rumors Eli Lilly (LLY) Is Planning to Acquire Biotech Firm Abivax

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly is advancing its mental health pipeline with a new Phas...

Eli Lilly Expands Bipolar Disorder Pipeline With New Phase 2 Brenipatide Trial

Traders will find the latest deals, analyst coverage, and economic data in the Monday wrap-up.


The pharma giant is also building a supercomputer. 


Eli Lilly (LLY) Partners with Nvidia on New AI Drug Laboratory

Tempus AI’s ($TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The up...

Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges

The obesity drug market is red-hot right now. 


Amazon (AMZN) Begins Selling Novo Nordisk’s Weight-Loss Pill

Insiders have been trading these 5 stocks: (($MU)), (($AVGO)), (($XYZ)), (($LLY)) and (($MRVL)). Here is a breakdown of their recent trades and the...

Micron, Broadcom, Block, Eli Lilly, Marvell: Insider Shake-Up

Danish pharma giant Novo Nordisk’s ($NVO) shares bubbled with life on Friday afternoon as retail giant Amazon’s ($AMZN) digital pharmacy kicked off...

Novo Nordisk Stock (NVO) Jumps as Amazon Begins Selling Obesity Pill

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co, with a price target of $1,300.00. Tewari covers ...

Jefferies Remains a Buy on Eli Lilly & Co (LLY)

Stocks are on the move Thursday alongside earnings reports, analyst updates, major deals, and more.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Ventyx Biosciences’ ($VTYX) shares rallied about 68% early Wednesday after reports of drugmaker Eli Lilly’s ($LLY) interest in acquiring the biopha...

Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts

TipRanks offers all of the hottest stock market news for Wednesday in its daily wrap-up.


The company’s drug pipeline is underappreciated, argues the bank. 


Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company has launched a Phase 3 tria...

Lilly’s New Phase 3 Obesity Trial Signals Long-Term Upside in Weight-Loss Market

The race for obesity-drug market share was one key highlight for Big Pharma in 2025. However, data shows the Big Pharma rally seen in 2025 is more ...

LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze

Ventyx Biosciences ($VTYX) stock rallied about 68% in Wednesday’s pre-market trading in reaction to a report by the Wall Street Journal about a pot...

M&A News: Ventyx Biosciences Stock (VTYX) Rallies on News of Potential Acquisition by Eli Lilly

Jefferies analyst Michael Yee initiated coverage with a Buy rating on Eli Lilly & Co today and set a price target of $1,250.00. According to TipRan...

Eli Lilly & Co (LLY) Receives a New Rating from Jefferies

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Ally Financial (ALLY – Research Report) and Morgan St...

Analysts Are Bullish on These Financial Stocks: Ally Financial (ALLY), Morgan Stanley (MS)

Traders looking for the latest stock market stories for Monday will find them in our daily wrap-up.


Lilly’s new weight-loss pill is expected this summer. 


Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on WisdomTree (WT – Research Report) and Ally Financial ...

Analysts Offer Insights on Financial Companies: WisdomTree (WT) and Ally Financial (ALLY)

The weight-loss war is moving from the needle to the medicine cabinet as Novo Nordisk ($NVO) officially launches its daily Wegovy pill in the Unite...

Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch

Analysts fell to the sidelines weighing in on Ally Financial (ALLY – Research Report) and eToro (ETOR – Research Report) with neutral ratings, indi...

Analysts Offer Insights on Financial Companies: Ally Financial (ALLY) and eToro (ETOR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IDEAYA Biosciences (IDYA – Research Report) and Eli ...

Current Quarter	$6.99	Next Quarter	$6.96
Current Year	$23.74	Next Year	$33.24
QoQ Growth	-0.4%	YoY Growth	+40.0%
3Y EPS CAGR	+24.1%	Target Price	$1163.88
Consensus	Buy	Upside	+16.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$999.80	-4.25%	3.85M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$999.80	-4.2%	3.85M
3
4
5
6

LLY

LLY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel